2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aminopeptidase
  5. Aminopeptidase Inhibitor

Aminopeptidase Inhibitor

Aminopeptidase Inhibitors (52):

Cat. No. Product Name Effect Purity
  • HY-15695
    Puromycin aminonucleoside
    		Inhibitor 99.90%
    Puromycin aminonucleoside (NSC 3056) is the aminonucleoside portion of the antibiotic puromycin, and used in nephrosis animal models. Puromycin aminonucleoside induces apoptosis. Puromycin aminonucleoside is a reversible inhibitor of dipeptidyl peptidase II and cytosol alanyl aminopeptidase. Puromycin aminonucleoside induces secretion of cell migrasome.
  • HY-B0134
    Bestatin
    		Inhibitor 99.97%
    Bestatin is a natural, broad-spectrum, and competitive CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase inhibitor. Bestatin has anticancer effects.
  • HY-113952
    Actinonin
    		Inhibitor 98.61%
    Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces. Actinonin inhibits aminopeptidase M, aminopeptidase N and leucine aminopeptidase. Actinonin is a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. Actinonin also inhibits MMP-1, MMP-3, MMP-8, MMP-9, and hmeprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin is an apoptosis inducer. Actinonin has antiproliferative and antitumor activities.
  • HY-B0134A
    Bestatin hydrochloride
    		Inhibitor 99.94%
    Bestatin hydrochloride is an inhibitor of CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase, used for cancer research.
  • HY-101932
    TNP-470
    		Inhibitor 99.87%
    TNP-470 is a methionine aminopeptidase-2 inhibitor and also an angiogenesis inhibitor.
  • HY-10826
    DG051 free acid
    		Inhibitor
    DG051 (free acid) is an effective inhibitor of leukotriene A4 hydrolase (LTA4H), with a Kd of 26 nM. It has high water solubility (greater than 30 mg/mL) and high oral bioavailability (over 80% across different species). DG051 (free acid) can be used in research related to myocardial infarction and stroke.
  • HY-118661
    BDM14471
    		Inhibitor
    BDM14471 is a selective inhibitor of hydroxamate aminopeptidase M1 (PfAM1), with the IC50 of 6 nM.
  • HY-B0494
    Bufexamac
    		Inhibitor ≥98.0%
    Bufexamac is a selective Ⅱb HDAC (HDAC6, HDAC10) and LTA4H dual inhibitor, with Kds of 0.53 µM and 0.22 µM for HDAC6 and HDAC10. Bufexamac is a nonsteroida anti-inflammatory drug.
  • HY-103226
    SC-57461A
    		Inhibitor 99.89%
    SC-57461A is a potent, orally active, nonpeptide, and selective inhibitor of Leukotriene A4 (LTA4) hydrolase with IC50s of 2.5 nM, 3 nM, and 23 nM for recombinant human, mouse, and rat LTA4 hydrolase, respectively.
  • HY-14807
    Tosedostat
    		Inhibitor 99.75%
    Tosedostat (CHR-2797) is an orally active aminopeptidase inhibitor. CHR-2797 exerts antiproliferative effects against a range of tumor cell lines.
  • HY-109058
    Firibastat
    		Inhibitor ≥98.0%
    Firibastat (QGC001), an orally active brain penetrating proagent of EC33, is a first-in-class brain aminopeptidase A (APA) inhibitor (Ki=200 nM). Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats.
  • HY-137298
    LTA4H-IN-1
    		Inhibitor 98.61%
    LTA4H-IN-1 is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC50 of 2 nM. LTA4H-IN-1 can be used for the research of inflammatory and autoimmune disorders.
  • HY-150504
    ERAP2-IN-1
    		Inhibitor 98.86%
    ERAP2-IN-1 (compound 61) is an uncompetitive ERAP2 inhibitor. ERAP2-IN-1 specifically inhibits the ERAP2 peptide hydrolysis activity, inhibiting Arg-AMC hydrolysis with an IC50 of 27 μM and model peptide hydrolysis with an IC50 of 44 μM.
  • HY-110259
    HFI-142
    		Inhibitor 99.55%
    HFI-142 is an insulin-regulated aminopeptidase (IRAP) inhibitor with a Ki of 2.01 μM.
  • HY-W015876
    L-Leucinol
    		Inhibitor 99.53%
    L-Leucinol ((+)-Leucinol) is a competitive aminopeptidase inhibitor with Ki value of 17 μM.
  • HY-160239
    HFI-437
    		Inhibitor 99.64%
    HFI-437 is a potent non-peptidic insulin-regulated aminopeptidase (IRAP) inhibitor with a Ki of 20 nM. HFI-437 is a cognitive enhancer.
  • HY-151518
    Aminopeptidase-IN-1
    		Inhibitor 98.02%
    Aminopeptidase-IN-1 (compound 16o) is a potent insulin-regulated aminopeptidase (IRAP) inhibitor with an Ki value of 7.7 μM. Aminopeptidase-IN-1 can be used tor research cognitive and memory impairments.
  • HY-W027340
    ARM1
    		Inhibitor 99.60%
    ARM1 (4BSA) is a potent aminopeptidase and epoxide hydrolase inhibitor. ARM1 shows aminopeptidase inhibitory activity with an IC50 7.61 µM and epoxide hydrolase inhibitory activity with an IC50 12.4 µM.
  • HY-10825
    DG051
    		Inhibitor 99.86%
    DG051 is a potent leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis in the enzyme assay with an IC50=47 nM.
  • HY-B0134AS
    Bestatin-d7 hydrochloride
    		Inhibitor
    Bestatin-d7 (hydrochloride) is deuterium labeled Bestatin (hydrochloride). Bestatin hydrochloride is an inhibitor of CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase, used for cancer research.